Pulmonx (LUNG) Common Equity (2019 - 2025)

Pulmonx (LUNG) has reported Common Equity for 7 consecutive years, with $54.1 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Common Equity fell 36.93% year-over-year to $54.1 million in Q4 2025; TTM through Dec 2025 was $54.1 million, a 36.93% decrease from a year earlier, with the FY2025 full-year figure at $54.1 million, down 36.93% from the prior year.
• Common Equity was $54.1 million for Q4 2025 at Pulmonx, down from $60.0 million in the prior quarter.
• Over five years, Common Equity peaked at $216.1 million in Q1 2021 and troughed at $54.1 million in Q4 2025.
• A 5-year average of $133.4 million and a median of $129.8 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity jumped 211.39% in 2021 and slumped 36.93% in 2025, its largest moves.
• Over 5 years, Common Equity stood at $193.2 million in 2021, then retreated by 20.3% to $154.0 million in 2022, then slipped by 23.18% to $118.3 million in 2023, then decreased by 27.47% to $85.8 million in 2024, then plunged by 36.93% to $54.1 million in 2025.
• The last three Common Equity figures came in at $54.1 million (Q4 2025), $60.0 million (Q3 2025), and $69.1 million (Q2 2025), per Business Quant data.